D. E. Shaw & Co. Inc. Has $450,000 Stock Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

D. E. Shaw & Co. Inc. lifted its position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 307.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 126,464 shares of the company’s stock after buying an additional 95,418 shares during the period. D. E. Shaw & Co. Inc. owned about 0.14% of Aquestive Therapeutics worth $450,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of AQST. Raymond James Financial Inc. bought a new position in Aquestive Therapeutics during the fourth quarter worth $498,000. Harvey Capital Management Inc. grew its position in shares of Aquestive Therapeutics by 1,419.3% during the 4th quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company’s stock worth $952,000 after purchasing an additional 249,790 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Aquestive Therapeutics by 1.9% during the 4th quarter. Vanguard Group Inc. now owns 4,346,754 shares of the company’s stock worth $15,474,000 after purchasing an additional 82,958 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Aquestive Therapeutics by 233.6% during the 4th quarter. Renaissance Technologies LLC now owns 95,400 shares of the company’s stock worth $340,000 after purchasing an additional 66,800 shares in the last quarter. Finally, SG Americas Securities LLC grew its position in shares of Aquestive Therapeutics by 28.7% during the 4th quarter. SG Americas Securities LLC now owns 32,966 shares of the company’s stock worth $117,000 after purchasing an additional 7,347 shares in the last quarter. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on AQST shares. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a research report on Thursday, May 15th. Lake Street Capital decreased their price target on Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, March 7th. Alliance Global Partners restated a “buy” rating on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Finally, Raymond James set a $7.00 price target on Aquestive Therapeutics in a research note on Friday, March 7th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $10.67.

Aquestive Therapeutics Stock Up 2.6%

Shares of Aquestive Therapeutics stock opened at $2.35 on Tuesday. The company’s fifty day moving average is $2.70 and its 200 day moving average is $3.22. The stock has a market cap of $233.42 million, a price-to-earnings ratio of -5.22 and a beta of 2.02. Aquestive Therapeutics, Inc. has a twelve month low of $2.12 and a twelve month high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Monday, May 12th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.07). The company had revenue of $8.72 million for the quarter, compared to analyst estimates of $12.23 million. As a group, equities analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.